<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Risk factors for and possible causes of systemic sclerosis (scleroderma)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Risk factors for and possible causes of systemic sclerosis (scleroderma)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Risk factors for and possible causes of systemic sclerosis (scleroderma)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Varga, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John S Axford, DSc, MD, FRCP, FRCPCH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of systemic sclerosis (SSc; scleroderma) involves vascular, fibrotic, inflammatory, and immunologic processes. Although a great deal is known about the abnormalities in immune, endothelial, and fibroblast cell function in SSc, it is unclear how these pathogenic pathways are initiated.
        </p>
        <p>
         The etiology of SSc is unknown. The remarkable complexity of its pathogenesis suggests that no single gene or environmental trigger is, by itself, likely to be responsible for the development of SSc. Nevertheless, genetic factors appear to influence disease susceptibility as well as patterns of disease expression and disease-associated autoantibodies. The occurrence of SSc-like disease in response to certain environmental agents and the possible relationship of SSc to environmental exposures suggest that certain triggers lead to variable disease expression in genetically susceptible hosts.
        </p>
        <p>
         A review of the risk factors for and possible causes of SSc is presented here. The pathogenesis of SSc, including vascular and endothelial changes, fibroblast activity, and the role of different cytokines, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7554.html" rel="external">
          "Pathogenesis of systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exposure to viruses or to certain environmental toxins and drugs appears to trigger the development of disease in genetically susceptible hosts.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          GENETIC FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence for genetic factors contributing to disease susceptibility in systemic sclerosis (SSc) comes from a variety of observations [
         <a href="#rid1">
          1
         </a>
         ]. Studies of the Choctaw Native Americans in Oklahoma showed that the prevalence of SSc was 20 times higher than in the general population [
         <a href="#rid2">
          2,3
         </a>
         ]. Furthermore, disease expression in this cohort was remarkably homogeneous, with diffuse skin disease, lung involvement, and anti-topoisomerase I (Scl-70) antibodies detected in almost all affected individuals. The risk of SSc in first-degree relatives of individuals with SSc is markedly increased.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Candidate genes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The strongest genetic associations linked to SSc are with the major histocompatibility complex (MHC). In the Choctaw Native American population, the presence of anti-topoisomerase I antibodies is strongly linked to the human leukocyte antigen (HLA) haplotype DQ7, DR2 (DRB1*1602) [
         <a href="#rid3">
          3,4
         </a>
         ]. Other risk-associated alleles are DQA1*0501 and DQB1*0301 [
         <a href="#rid3">
          3
         </a>
         ]. Subsequent studies showed a link between the fibrillin-1 gene, implicated in a putative mouse model of inherited scleroderma [
         <a href="#rid5">
          5
         </a>
         ], and SSc in this Native American population [
         <a href="#rid6">
          6
         </a>
         ], but not in White French or Italian populations [
         <a href="#rid7">
          7
         </a>
         ]. Neither the MHC nor the fibrillin-1 gene shows a perfect association with the disease; there are affected individuals without the suspect genes and unaffected individuals with these genes.
        </p>
        <p>
         Genes in the MHC influence disease susceptibility [
         <a href="#rid8">
          8-12
         </a>
         ]. As an example, the HLA-DQA1*0501 allele was found in 42 percent of White men with diffuse cutaneous SSc but in only 29 percent of healthy men from the same geographic area (odds ratio 3) [
         <a href="#rid8">
          8
         </a>
         ]. Risk associations have also been suggested to exist between SSc and HLA-DR5/11 and DR3 haplotypes in White individuals, DR2 haplotypes in Japanese, and, as noted above, DR2 (DRB1*1602) in the Choctaw population [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         There is also an association between HLA and certain SSc-specific autoantibodies. These include antibodies directed against fibrillarin [
         <a href="#rid13">
          13
         </a>
         ], ribonucleic acid (RNA) polymerase [
         <a href="#rid14">
          14
         </a>
         ], anticentromere [
         <a href="#rid3">
          3
         </a>
         ], anti-PM-Scl [
         <a href="#rid3">
          3
         </a>
         ], and topoisomerase I [
         <a href="#rid3">
          3,15,16
         </a>
         ].
        </p>
        <p>
         Genetic polymorphisms in non-MHC genes associated with SSc include angiotensin converting enzyme (
         <em>
          ACE
         </em>
         ), endothelial nitric oxide synthase (
         <em>
          eNOS
         </em>
         ), the B cell surface protein associated with the antigen receptor (
         <em>
          CD19
         </em>
         ), and
         <em>
          PTPN22
         </em>
         [
         <a href="#rid17">
          17-20
         </a>
         ]. However, the putative association between
         <em>
          ACE
         </em>
         and
         <em>
          eNOS
         </em>
         polymorphisms and SSc could not be independently confirmed [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H88469500">
         <span class="h2">
          Genome-wide association studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genome-wide screening in a case-control study in the Choctaw population confirmed earlier candidate gene regions (eg, MHC and the fibrillin gene) and identified other sites dispersed on several chromosomes that were associated with disease [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         The largest genome-wide association study (GWAS) examined 2753 patients with SSc (mostly of European ancestry) and 5171 controls [
         <a href="#rid22">
          22
         </a>
         ]. Several susceptibility loci were identified, including the HLA locus and gene regions for
         <em>
          CD247
         </em>
         , interferon regulatory factor 5 (
         <em>
          IRF5
         </em>
         ), and signal transducer and activator of transcription 4 (
         <em>
          STAT4
         </em>
         ). Each of these SSc-susceptibility loci is involved in immune recognition, in innate immunity, or in immune cell signaling. Interestingly, a majority of gene variants associated with SSc have also been linked to other autoimmune diseases, particularly systemic lupus erythematosus (SLE) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4251370">
         <span class="h2">
          Familial clustering
         </span>
         <span class="headingEndMark">
          —
         </span>
         Further support for a genetic basis of SSc is provided by familial clustering of SSc or autoimmune disorders. One study of 710 families with one member having SSc reported a 1.4 percent incidence in another family member [
         <a href="#rid24">
          24
         </a>
         ]. Similar frequencies have been observed in other studies (1.5 to 2.5 percent) [
         <a href="#rid25">
          25,26
         </a>
         ]. The increased risk is similar for siblings and other first-degree relatives of affected patients (15- and 13-fold higher, respectively) [
         <a href="#rid3">
          3
         </a>
         ]. Familial studies of autoantibodies in SSc are consistent with the hypothesis that genetic factors might determine whether disease develops and which phenotype is expressed. Although monozygotic twins are only modestly concordant for SSc (4.7 percent), they are 90 percent concordant for antinuclear antibody (ANA) positivity (titer of ≥1:40) [
         <a href="#rid3">
          3,27
         </a>
         ]. Similarly, family members of patients with SSc are much more likely to have ANA than are healthy controls [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Non-HLA gene associations with systemic sclerosis
         </span>
        </p>
        <p class="headingAnchor" id="H1645998773">
         <span class="h3">
          PTPN22 gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         A polymorphism of the
         <em>
          PTPN22
         </em>
         gene was associated with the finding of anticentromere and anti-topoisomerase antibodies in SSc patients [
         <a href="#rid20">
          20,30
         </a>
         ]. This gene has also been reported to be important in a number of other autoimmune conditions, including diabetes mellitus-type I, rheumatoid arthritis, SLE, Grave disease, and juvenile idiopathic arthritis (JIA) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2021575972">
         <span class="h3">
          IRF8 gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         A polymorphism in the
         <em>
          IRF8
         </em>
         gene was found by GWAS to be protective for SSc disease susceptibility [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2499067463">
         <span class="h3">
          TNFAIP3 (A20) gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         A polymorphism of the
         <em>
          TNFAIP3
         </em>
         gene was found to be associated with diffuse cutaneous SSc and was further associated with interstitial lung disease and pulmonary hypertension [
         <a href="#rid33">
          33
         </a>
         ]. Multiple polymorphic variants in this gene, encoding the immunomodulatory enzyme A20, have been associated with SLE and other autoimmune and inflammatory diseases.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          IFN regulatory factor 5 gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a study of 427 patients with SSc, an association was noted between a functional polymorphism of the
         <em>
          IRF5
         </em>
         gene and the risk of scleroderma (odds ratio 1.59, 95% CI 1.18-2.11) [
         <a href="#rid34">
          34
         </a>
         ]. Carriage of the risk allele was also associated with an increased risk of fibrosing alveolitis in White European ancestry. International GWAS have identified
         <em>
          IRF5
         </em>
         as a susceptibility locus for SSc in a European population [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other recurrent genes associated with SSc or specific SSc subsets include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          STAT4
         </em>
         , the signal transducer and activator of transcription 4 gene [
         <a href="#rid35">
          35,36
         </a>
         ], is a transcription factor implicated in inflammatory signaling. Several studies have indicated an association of polymorphisms in
         <em>
          STAT4
         </em>
         with SSc. Moreover, polymorphisms in
         <em>
          STAT4
         </em>
         have additive effects with polymorphisms in
         <em>
          IRF5
         </em>
         on SSc-associated interstitial lung disease [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          BANK1
         </em>
         , a substrate of tyrosine kinase expressed on B cells, with a stronger association of the combination of
         <em>
          BANK1
         </em>
         ,
         <em>
          STAT4
         </em>
         , and
         <em>
          IRF5
         </em>
         alleles with diffuse cutaneous systemic sclerosis (dcSSc) [
         <a href="#rid37">
          37
         </a>
         ]. These gene associations, together with another B-cell related gene
         <em>
          BLK
         </em>
         , implicate B cells in SSc pathogenesis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          CD247
         </em>
         gene – Polymorphisms of the
         <em>
          CD247
         </em>
         gene implicated in T-cell activation were found to be associated with SSc by GWAS [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          TBX21
         </em>
         gene [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          HLA-DPB1
         </em>
         and
         <em>
          -DPB2
         </em>
         [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Interleukin (IL)-23 receptor polymorphisms associated with pulmonary hypertension and anti-topoisomerase-I [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          TNIP-1
         </em>
         gene – Polymorphisms in the
         <em>
          TNIP-1
         </em>
         gene (encoding NTFAIP3-interacting protein) were associated with SSc in GWAS [
         <a href="#rid41">
          41
         </a>
         ]. Skin biopsies from patients with SSc showed reduced expression of this protein.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          INFECTIOUS AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic factors alone cannot fully explain disease expression. Thus, one hypothesis is that infection, particularly with a virus, may trigger a cascade of events in a genetically susceptible host leading to systemic sclerosis (SSc) and associated autoimmunity.
        </p>
        <p>
         One possibility is that viruses harboring amino acid sequences similar to those found within host proteins may initiate the disease process in a host HLA haplotype-restricted manner. This general phenomenon, not unique to SSc, is called molecular mimicry. One study described a common epitope shared between topoisomerase I, a key target autoantigen in SSc, and certain retroviruses [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Latent viral infection may also accelerate or promote disease in the susceptible host. In particular, cytomegalovirus may induce the vascular, fibrotic, and immunologic features of SSc via effects on various cell types:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection of endothelial cells results in vascular and immune injury [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The virus can subvert immune responses.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fibrosis is promoted by stimulating production of transforming growth factor (TGF)-beta, connective tissue growth factor, and related cytokines [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Studies have suggested that SSc-specific autoantibodies react with the UL94 human cytomegalovirus late protein. These autoantibodies were able to induce endothelial cell apoptosis [
         <a href="#rid44">
          44
         </a>
         ] and also to activate cultured human fibroblasts [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Studies from Europe suggest that localized scleroderma (morphea) may be associated with Borrelia burgdorferi infection [
         <a href="#rid46">
          46,47
         </a>
         ]. A similar association has not been seen in the United States. (See
         <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">
          "Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          NONINFECTIOUS ENVIRONMENTAL FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of environmental agents have been implicated in systemic sclerosis (SSc), based upon case clustering or upon formal epidemiological studies. One of the earliest and strongest such associations, with silica dust, was discovered because of the high frequency of SSc among stone masons [
         <a href="#rid48">
          48
         </a>
         ]. Similar clustering has been observed among gold miners in South Africa and among coal miners in the United States [
         <a href="#rid49">
          49,50
         </a>
         ]. However, a case-control study from the United Kingdom did not support an association of SSc with occupational silica exposure [
         <a href="#rid51">
          51
         </a>
         ]. Since the use of vibrating machinery is associated with the Raynaud phenomenon [
         <a href="#rid52">
          52
         </a>
         ] and since silica may cause interstitial lung disease (silicosis), some cases described as SSc may instead have had the confluence of these two disorders.
        </p>
        <p>
         A meta-analysis of 16 observational studies, which examined the risk of occupational silica exposure, found that such exposure was associated with significant risk for the development of SSc in males (combined estimator of relative risk [CERR] 3, 95% CI 1.2-7.4), but not in females (CERR 1, 95% CI 0.7-1.4) [
         <a href="#rid53">
          53
         </a>
         ]. The risk estimate in cohort studies was higher than the estimate in case-control studies (CERR 15.4 versus 2.2).
        </p>
        <p>
         Despite concern about a possible relationship between silicone exposure, primarily in breast implant recipients, and SSc or SSc-like disease, multiple large epidemiologic studies and a meta-analysis failed to provide evidence supporting a relationship. In one study, the prevalence rates for SSc and other autoimmune disorders were compared among 1576 women with breast implants (of whom 1112 had received silicone gel-filled implants) and 726 control individuals [
         <a href="#rid54">
          54
         </a>
         ]. The incidences of typical or atypical connective tissue disease, as determined by a rheumatologist, were similar between the two groups.
        </p>
        <p>
         Similarly, in a meta-analysis of nine cohort studies, nine case-control studies, and two cross-sectional studies, breast implants in general and silicone-filled breast implants in particular were not associated with an enhanced risk of SSc or other connective tissue disease [
         <a href="#rid55">
          55
         </a>
         ]. This topic is further addressed elsewhere.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Petroleum-based products
         </span>
         <span class="headingEndMark">
          —
         </span>
         A relationship between certain toxic exposures and SSc or SSc-like syndromes is supported by some studies. Examples include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 178 patients with SSc and 200 control individuals, men with the disorder had higher cumulative exposure to organic solvents than did controls [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 660 women with SSc and 2227 controls, exposure to paint removers and paint thinners (but not to trichloroethylene [TCE]) was significantly more likely in the SSc group [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         There are reports of linkage of SSc with certain industrial solvents. Trichloroethane (TCA), TCE, toluene, and xylene are among those most frequently cited. TCE has a similar structure to vinyl chloride. In addition, an association between solvent-associated hobbies and the development of SSc with anti-topoisomerase I antibodies has been reported [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         An association between exposure to petroleum distillates and undifferentiated connective tissue disease was suggested by an epidemiologic study [
         <a href="#rid59">
          59
         </a>
         ]. Potentially implicated compounds included hydrocarbons such as paint thinners, benzene, and chlorinated solvents such as TCA and TCE.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Vinyl chloride
         </span>
         <span class="headingEndMark">
          —
         </span>
         An SSc-like disease has been reported in individuals exposed to vinyl chloride monomer [
         <a href="#rid60">
          60
         </a>
         ]. This exposure occurs in the manufacturing process of vinyl chloride polymer and not in connection with any finished product. Affected individuals had SSc-like vascular features including Raynaud phenomenon, telangiectasia, and nailfold capillary changes but did not display characteristic skin changes.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Contaminated rapeseed oil
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ingestion of contaminated rapeseed oil was associated with a self-limited epidemic illness called toxic oil syndrome in Spain in the early 1980s. The syndrome was characterized by acute myalgia, fever, neuropathy, SSc-like skin disease, and pulmonary hypertension [
         <a href="#rid61">
          61
         </a>
         ]. The disease was temporally closely related to the rapeseed oil exposure.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          L-tryptophan
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another exposure linked to a toxic-epidemic SSc-like illness is eosinophilia myalgia syndrome (EMS), which occurred in the United States in the late 1980s. This illness, characterized by fasciitis and dermal induration, occurred in individuals consuming the nutritional supplement L-tryptophan [
         <a href="#rid62">
          62-64
         </a>
         ]. Affected individuals showed abrupt onset of chronic diffuse skin induration, as well as neuropathy and myopathic features, but, in marked distinction to SSc, they did not have the Raynaud phenomenon, SSc-specific autoantibodies, or visceral disease [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         The syndrome showed clinical similarities to the toxic oil syndrome described above and was linked to the consumption of L-tryptophan, particularly specific batches originating from a single manufacturer in Japan.
        </p>
        <p>
         A well-documented post-epidemic case of EMS was described in an individual who used L-tryptophan subsequent to the 2005 lifting of the US Food and Drug Administration (FDA) ban on L-tryptophan in the United States imposed following the identification of the syndrome and its link to the specific contaminant [
         <a href="#rid65">
          65
         </a>
         ]. This case highlights the continued occurrence of L-tryptophan-associated EMS. Sporadic cases meeting surveillance criteria for EMS but lacking L-tryptophan exposure have also been reported [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         In addition to a significant positive association with L-tryptophan dose and increased age, both increased risk of EMS and protection following exposure have been associated with certain class II histocompatibility gene polymorphisms [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         Another dietary supplement, 5-hydroxytryptophan (5-HTP) has been associated with an EMS-like disorder [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several drugs have been associated with the development of systemic sclerosis (SSc)-like syndromes. Best studied of these is
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         , which induces skin and lung fibrosis in animal models [
         <a href="#rid69">
          69
         </a>
         ]. Several cases of SSc with the Raynaud phenomenon have been reported among cancer patients undergoing chemotherapy with bleomycin [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">
          "Cutaneous adverse effects of conventional chemotherapy agents"
         </a>
         .)
        </p>
        <p>
         A mechanism potentially underlying the possible role of
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         in SSc-like conditions is the induction of chromosome breaks, a phenomenon that is enhanced with bleomycin ingestion and is seen in patients with SSc and their family members, independent of drug exposure [
         <a href="#rid71">
          71,72
         </a>
         ]. Chromosome breaks may occur in response to oxidative stress, which may preferentially lead to the formation and release of unique autoantigens [
         <a href="#rid73">
          73,74
         </a>
         ].
        </p>
        <p>
         Other drugs potentially implicated in SSc-like syndromes include
         <a class="drug drug_general" data-topicid="9753" href="/z/d/drug information/9753.html" rel="external">
          pentazocine
         </a>
         , cocaine, and the taxanes
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         and
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          MICROCHIMERISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Healthy women frequently harbor viable immunologic stem cells of fetal origin many years following pregnancy [
         <a href="#rid76">
          76
         </a>
         ]. The number of circulating fetal cells present in women with systemic sclerosis (SSc) who have been pregnant is elevated compared with healthy control women with a history of pregnancy [
         <a href="#rid77">
          77,78
         </a>
         ]. Male cells were found in at least one organ obtained at autopsy from women with SSc who had male offspring [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         The persistence of fetal cells may be linked to the pathogenesis of SSc via several potential mechanisms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal (the graft) cells may mount an immune response against the mother (the host) in a graft-versus-host-like reaction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A maternal response to the fetal cells may subsequently be redirected against "self," leading to autoimmunity. It is noteworthy that patients with SSc are more likely to be closely human leukocyte antigen (HLA)-matched to the paternal HLA carried by their children [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maternal cells that cross the placenta and that are carried by the fetus may play an immunomodulatory role in men with SSc or in women with SSc who have never been pregnant [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         However, not all studies have confirmed the increase in microchimerism in SSc. Furthermore, one's immunogenetic background may determine the development of microchimerism; as an example, among individuals with HLA-DQA1*0501, microchimerism was increased both in patients with SSc and in healthy controls [
         <a href="#rid81">
          81
         </a>
         ]. Therefore, the significance of fetal microchimerism in the pathogenesis of SSc remains uncertain.
        </p>
        <p class="headingAnchor" id="H2316612">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic factors
         </strong>
         – Familial clustering of disease and gene associations suggest a role for genetic influences in systemic sclerosis (SSc; scleroderma).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MHC class II
         </strong>
         – The genetic findings include associations with certain major histocompatibility antigen (MHC) class II alleles and other genes involved in immune recognition or signaling.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          HLA haplotypes
         </strong>
         – There is also an association between human leukocyte antigen (HLA) haplotypes and certain SSc-specific autoantibodies. (See
         <a class="local">
          'Candidate genes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other genetic factors
         </strong>
         – Non-HLA genes linked to SSc susceptibility include
         <em>
          TNFAIP3
         </em>
         ,
         <em>
          CD247
         </em>
         , and
         <em>
          PTPN22
         </em>
         genes as well as genes for interferon regulatory factor 5 (IRF5). (See
         <a class="local">
          'Non-HLA gene associations with systemic sclerosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Environmental factors
         </strong>
         – A number of environmental exposures have been linked to SSc based upon case clustering or formal epidemiological studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Silica
         </strong>
         – Occupational silica exposure in males is associated with a significant increase in SSc risk. However, there is no evidence of a relationship between silicone exposure from breast implants and the development of SSc or SSc-like disease. (See
         <a class="local">
          'Noninfectious environmental factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Infection
         </strong>
         – Infection may play a role in SSc pathogenesis. Potential mechanisms include molecular mimicry or more direct cellular effects of latent viral infection, such as cytomegalovirus, which may induce the vascular, fibrotic, and immunologic features of SSc. (See
         <a class="local">
          'Infectious agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Toxins
         </strong>
         – A relationship between certain toxic exposures and SSc or SSc-like syndromes has been observed for several substances. (See
         <a class="local">
          'Noninfectious environmental factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Exposure to organic solvents has been associated with the development of SSc.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         SSc-like disorders may occur in patients exposed to vinyl chloride,
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         , and several other medications.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Local epidemics of SSc-like disorders have occurred in association with contaminated rapeseed oil (ie, toxic oil syndrome) and contaminated L-tryptophan (ie, eosinophilia myalgia syndrome [EMS]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microchimerism
         </strong>
         – Some studies have suggested a potential role for increased microchimerism (ie, circulating fetal deoxyribonucleic acid [DNA] in the parent or parental DNA in the offspring) in SSc. (See
         <a class="local">
          'Microchimerism'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol 2018; 32:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnett FC, Howard RF, Tan F, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum 1996; 39:1362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal SK, Tan FK, Arnett FC. Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am 2008; 34:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan FK, Stivers DN, Arnett FC, et al. HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). Tissue Antigens 1999; 53:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siracusa LD, McGrath R, Ma Q, et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996; 6:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan FK, Stivers DN, Foster MW, et al. Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum 1998; 41:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wipff J, Giraud M, Sibilia J, et al. Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. J Rheumatol 2008; 35:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambert NC, Distler O, Müller-Ladner U, et al. HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men. Arthritis Rheum 2000; 43:2005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnett FC, Bias WB, McLean RH, et al. Connective tissue disease in southeast Georgia. A community based study of immunogenetic markers and autoantibodies. J Rheumatol 1990; 17:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladman DD, Keystone EC, Baron M, et al. Increased frequency of HLA-DR5 in scleroderma. Arthritis Rheum 1981; 24:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuwana M, Kaburaki J, Okano Y, et al. The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J Clin Invest 1993; 92:1296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladman DD, Kung TN, Siannis F, et al. HLA markers for susceptibility and expression in scleroderma. J Rheumatol 2005; 32:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnett FC, Reveille JD, Goldstein R, et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996; 39:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fanning GC, Welsh KI, Bunn C, et al. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol 1998; 37:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigolo B, Mazzetti I, Meliconi R, et al. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin Exp Immunol 2000; 121:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rands AL, Whyte J, Cox B, et al. MHC class II associations with autoantibody and T cell immune responses to the scleroderma autoantigen topoisomerase I. J Autoimmun 2000; 15:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fatini C, Gensini F, Sticchi E, et al. High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med 2002; 112:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuchiya N, Kuroki K, Fujimoto M, et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 2004; 50:4002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assassi S, Mayes MD, McNearney T, et al. Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis. Am J Med 2005; 118:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gourh P, Tan FK, Assassi S, et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 2006; 54:3945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou X, Tan FK, Wang N, et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003; 48:2585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010; 42:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assassi S, Radstake TR, Mayes MD, Martin J. Genetics of scleroderma: implications for personalized medicine? BMC Med 2013; 11:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Englert H, Small-McMahon J, Chambers P, et al. Familial risk estimation in systemic sclerosis. Aust N Z J Med 1999; 29:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001; 44:1359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assassi S, Arnett FC, Reveille JD, et al. Clinical, immunologic, and genetic features of familial systemic sclerosis. Arthritis Rheum 2007; 56:2031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48:1956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddison PJ, Skinner RP, Pereira RS, et al. Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis. Ann Rheum Dis 1986; 45:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddison PJ, Stephens C, Briggs D, et al. Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. The United Kingdom Systemic Sclerosis Study Group. Medicine (Baltimore) 1993; 72:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieudé P, Guedj M, Wipff J, et al. The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. Arthritis Rheum 2008; 58:2183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YH, Rho YH, Choi SJ, et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis. Rheumatology (Oxford) 2007; 46:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorlova O, Martin JE, Rueda B, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 2011; 7:e1002178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieudé P, Guedj M, Wipff J, et al. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis 2010; 69:1958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieudé P, Guedj M, Wipff J, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009; 60:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009; 18:2071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieudé P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009; 60:2472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieudé P, Wipff J, Guedj M, et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum 2009; 60:3447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gourh P, Agarwal SK, Divecha D, et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009; 60:3794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou X, Lee JE, Arnett FC, et al. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum 2009; 60:3807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal SK, Gourh P, Shete S, et al. Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis. J Rheumatol 2009; 36:2715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allanore Y, Saad M, Dieudé P, et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 2011; 7:e1002091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maul GG, Jimenez SA, Riggs E, Ziemnicka-Kotula D. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc Natl Acad Sci U S A 1989; 86:8492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamamdzic D, Harley RA, Hazen-Martin D, LeRoy EC. MCMV induces neointima in IFN-gammaR-/- mice: intimal cell apoptosis and persistent proliferation of myofibroblasts. BMC Musculoskelet Disord 2001; 2:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lunardi C, Bason C, Navone R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000; 6:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lunardi C, Dolcino M, Peterlana D, et al. Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 2006; 3:e2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bramwell B. Diffuse scleroderma: Its frequency; its occurrence in stonemasons; its treatment by fibrolysin-elevations of temperature due to fibrolysin injections. Edinburgh Med J 1914; 12:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisendle K, Grabner T, Zelger B. Morphoea: a manifestation of infection with Borrelia species? Br J Dermatol 2007; 157:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ERASMUS LD. Scleroderma in goldminers on the Witwatersrand with particular reference to pulmonary manifestations. S Afr J Lab Clin Med 1957; 3:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodnan GP, Benedek TG, Medsger TA Jr, Cammarata RJ. The association of progressive systemic sclerosis (scleroderma) with coal miners' pneumoconiosis and other forms of silicosis. Ann Intern Med 1967; 66:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silman AJ, Jones S. What is the contribution of occupational environmental factors to the occurrence of scleroderma in men? Ann Rheum Dis 1992; 51:1322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blair HM 3rd, Headington JT, Lynch PJ. Occupational trauma, Raynaud phenomenon, and sclerodactylia. Arch Environ Health 1974; 28:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns CJ, Laing TJ, Gillespie BW, et al. The epidemiology of scleroderma among women: assessment of risk from exposure to silicone and silica. J Rheumatol 1996; 23:1904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormic ZD, Khuder SS, Aryal BK, et al. Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. Int Arch Occup Environ Health 2010; 83:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edworthy SM, Martin L, Barr SG, et al. A clinical study of the relationship between silicone breast implants and connective tissue disease. J Rheumatol 1998; 25:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med 2000; 342:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nietert PJ, Sutherland SE, Silver RM, et al. Is occupational organic solvent exposure a risk factor for scleroderma? Arthritis Rheum 1998; 41:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maître A, Hours M, Bonneterre V, et al. Systemic sclerosis and occupational risk factors: role of solvents and cleaning products. J Rheumatol 2004; 31:2395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacey JV Jr, Garabrant DH, Laing TJ, et al. Petroleum distillate solvents as risk factors for undifferentiated connective tissue disease (UCTD). Am J Epidemiol 1999; 149:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol 1992; 19:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabuenca JM. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 1981; 2:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990; 323:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silver RM, Heyes MP, Maize JC, et al. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med 1990; 322:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varga J, Peltonen J, Uitto J, Jimenez S. Development of diffuse fasciitis with eosinophilia during L-tryptophan treatment: demonstration of elevated type I collagen gene expression in affected tissues. A clinicopathologic study of four patients. Ann Intern Med 1990; 112:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varga J, Heiman-Patterson TD, Emery DL, et al. Clinical spectrum of the systemic manifestations of the eosinophilia-myalgia syndrome. Semin Arthritis Rheum 1990; 19:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen JA, Peterson A, Sufit R, et al. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum 2011; 63:3633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan EA, Staehling N, Philen RM. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases. J Rheumatol 1996; 23:1784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okada S, Kamb ML, Pandey JP, et al. Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms. Arthritis Rheum 2009; 61:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michelson D, Page SW, Casey R, et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J Rheumatol 1994; 21:2261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu M, Varga J. In perspective: murine models of scleroderma. Curr Rheumatol Rep 2008; 10:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finch WR, Rodnan GP, Buckingham RB, et al. Bleomycin-induced scleroderma. J Rheumatol 1980; 7:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emerit I, Filipe P, Meunier P, et al. Clastogenic activity in the plasma of scleroderma patients: a biomarker of oxidative stress. Dermatology 1997; 194:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schachna L, Wigley FM, Morris S, et al. Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum 2002; 46:1873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 1997; 185:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bianchi DW, Zickwolf GK, Weil GJ, et al. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci U S A 1996; 93:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Angelis R, Bugatti L, Cerioni A, et al. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol 2003; 22:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JL, Furst DE, Maloney S, et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998; 351:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Artlett CM, Welsh KI, Black CM, Jimenez SA. Fetal-maternal HLA compatibility confers susceptibility to systemic sclerosis. Immunogenetics 1997; 47:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson KL, Nelson JL, Furst DE, et al. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis. Arthritis Rheum 2001; 44:1848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Artlett CM, Cox LA, Jimenez SA. Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA-Cw antigens. Arthritis Rheum 2000; 43:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maloney S, Smith A, Furst DE, et al. Microchimerism of maternal origin persists into adult life. J Clin Invest 1999; 104:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambert NC, Evans PC, Hashizumi TL, et al. Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity. J Immunol 2000; 164:5545.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7557 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30527428" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8702445" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18329530" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Genetics and genomic studies in scleroderma (systemic sclerosis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10082433" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8723723" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9778214" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18278837" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11014350" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1976808" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Connective tissue disease in southeast Georgia. A community based study of immunogenetic markers and autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6972768" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Increased frequency of HLA-DR5 in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7690776" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16078323" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : HLA markers for susceptibility and expression in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8670324" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9569077" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10971522" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11090244" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : MHC class II associations with autoantibody and T cell immune responses to the scleroderma autoantigen topoisomerase I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12015245" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15593213" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16084185" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17133608" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13130478" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20383147" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23311619" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Genetics of scleroderma: implications for personalized medicine?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10200811" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Familial risk estimation in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11407695" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17530643" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clinical, immunologic, and genetic features of familial systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12847690" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3098192" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8479323" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. The United Kingdom Systemic Sclerosis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18576360" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16760194" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21779181" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20511617" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19116937" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19286670" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19644887" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19877059" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19950257" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19950302" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19918037" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21750679" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2479024" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11518546" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : MCMV induces neointima in IFN-gammaR-/- mice: intimal cell apoptosis and persistent proliferation of myofibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11017152" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16318412" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Diffuse scleroderma: Its frequency; its occurrence in stonemasons; its treatment by fibrolysin-elevations of temperature due to fibrolysin injections
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17941947" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Morphoea: a manifestation of infection with Borrelia species?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13495613" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Scleroderma in goldminers on the Witwatersrand with particular reference to pulmonary manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4224922" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The association of progressive systemic sclerosis (scleroderma) with coal miners' pneumoconiosis and other forms of silicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1336652" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : What is the contribution of occupational environmental factors to the occurrence of scleroderma in men?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4809918" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Occupational trauma, Raynaud phenomenon, and sclerodactylia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8923364" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The epidemiology of scleroderma among women: assessment of risk from exposure to silicone and silica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20047060" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Occupational silica exposure as a risk factor for scleroderma: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9489816" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A clinical study of the relationship between silicone breast implants and connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10717013" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9627022" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Is occupational organic solvent exposure a risk factor for scleroderma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15570640" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Systemic sclerosis and occupational risk factors: role of solvents and cleaning products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10206626" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Petroleum distillate solvents as risk factors for undifferentiated connective tissue disease (UCTD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1378497" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Scleroderma in association with the use of bleomycin: a report of 3 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6116011" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2370887" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1690352" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2306063" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Development of diffuse fasciitis with eosinophilia during L-tryptophan treatment: demonstration of elevated type I collagen gene expression in affected tissues. A clinicopathologic study of four patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2164712" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Clinical spectrum of the systemic manifestations of the eosinophilia-myalgia syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21702023" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8895159" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19790128" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7699627" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18638424" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : In perspective: murine models of scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6160247" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Bleomycin-induced scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9094462" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Clastogenic activity in the plasma of scleroderma patients: a biomarker of oxidative stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12124872" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8996243" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8570620" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12605319" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9492775" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Microchimerism and HLA-compatible relationships of pregnancy in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9382916" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Fetal-maternal HLA compatibility confers susceptibility to systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11508438" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10817560" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA-Cw antigens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10393697" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Microchimerism of maternal origin persists into adult life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10820227" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
